Pancreatic Cancer Research

ResearcherCase Western Reserve UniversityNo recent work listed

Shuiliang Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9685-7433; OpenAlex author ID A5101736876; NIH RePORTER profile ID 12590236. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
1
Collaborators
8
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 grant · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 4

  1. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling. Co-author DOI 10.1186/s13046-022-02261-0↗
  2. CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression. Co-author DOI 10.18632/oncotarget.14194↗
  3. Cellular Prion Protein Mediates Pancreatic Cancer Cell Survival and Invasion through Association with and Enhanced Signaling of Notch1. First author DOI 10.1016/j.ajpath.2016.07.010↗
  4. CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic condition… Co-author DOI 10.1016/j.humpath.2014.01.014↗

Grants 1

  1. Role of CRABP-II in pancreatic cancer metastasis R03CA201738↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lan Zhou · 4 shared papers, 1 shared grant, 2014–2022 · strength 0.68
  2. Wei Xin · 4 shared papers, 2014–2022 · strength 0.34
  3. Ming Li · 2 shared papers, 2017–2022 · strength 0.24
  4. Lei Wang · 1 shared paper, 2022 · strength 0.16
  5. Yiwei Wang · 2 shared papers, 2016–2017 · strength 0.12
  6. Mark W. Jackson · 2 shared papers, 2016–2017 · strength 0.12
  7. Wenbin Xiao · 1 shared paper, 2014 · strength 0.05
  8. Man‐Sun Sy · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.